References

1. Bar-on ME, Zanga JR. Bronchiolitis. Prim Care. 1996;23:805-819.

2. Brunell PA. The respiratory season is upon us. Infectious Diseases in Children. Thorofare, NJ: Slack Inc; 1997;10(1):5.

3. Fete TJ, Noyes B. Common (but not always considered) viral infections of the lower respiratory tract. Pediatr Ann. 1996;25(10):577-584.

4. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995;95(issue 4):500-505.

5. Update: respiratory syncytial virus activity--United States, 1994-95 season. MMWR. 1994;43:920-923.

6. Englund JA, Sullivan CJ, Jordan C, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 1988;109:203-208.

7. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992;165:987-993.

8. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. Philadelphia, Pa: W.B. Saunders Co;1981:1247-1267.

9. Jeng M-J, Lemen RJ. Respiratory syncytial virus bronciolitis. Am Fam Physician. 1997;55:1139-1146.

10. Long CE, McBride JT, Hall CB. Sequelae of respiratory syncytial virus infections: a role for intervention studies. Am J Respir Crit Care Med. 1995;151:1678-1681.

11. Pullan CR, Hey EN. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. BMJ. 1982;284:1665-1669.

12. Henry RL, Hodges IGC, Milner AD, Stokes GM. Respiratory problems 2 years after acute bronchiolitis in infancy. Arch Dis Child. 1983;58:713-716.

13. Welliver RC, Doffy L. The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing, and pulmonary function at age 7-8 years. Pediatr Pulmonol. 1993;15:19-27.

14. Mok JYQ, Simpson H. Symptoms, atopy, and bronchial reactivity after lower respiratory infection in infancy. Arch Dis Child. 1984;59:299-305.

15. Korppi M, Reijonen T, Poysa L, Juntunen-Backman K. A 2- to 3-year outcome after bronchiolitis. Am J Dis Child. 1993;147:628-631.

16. Gurwitz D, Mindorff C, Levinson H. Increased evidence of bronchial reactivity in children with a history of bronchiolitis. J Pediatr. 1981;98:551-555.

17. Webb MSC, Henry RL, Milner AD, Stokes GM, Swarbuck AS. Continuing respiratory problems three and a half years after acute viral bronchiolitis. Arch Dis Child. 1985;60:1064-1067.

18. Sly PD, Hibbert ME. Childhood asthma following hospitalization with acute viral bronchiolitis in infancy. Pediatr Pulmonol. 1989;7:153-158.

19. Hall CB, Hall WJ, Gala CL, MaGill FB, Leddy JP. Long-term prospective study in children after respiratory syncytial virus infection. J Pediatr. 1984;105:358-364.

20. Shaw KN, Bell LM, Sherman NH. Outpatient assessment of infants with bronchiolitis. Am J Dis Child. 1991;145:151-155.

21. Rooney JC, Williams HE. The relationship between proved viral bronchiolitis and subsequent wheezing. J Pediatr. 1971;79:744-747.

22. Krilov LR, Mandel FS, Barone SR, Fagin JC and The Bronchiolitis Study Group. Follow-up of the children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. Pediatr Infect Dis J. 1997;16:273-6.

23. Jamie E. Fergie, Richard K. Purcell, Diane M. Wanat, Steve D. Seidel. Two Year Outcome of Children Hospitalized with RSV Lower Respiratory Tract Infection (LTRI) and its Relation to Ribavirin (R) Treatment. Pediatric Academic Societies Annual Meeting; May 1-5, 1998;Abstract#834.

24. Rodriguez WJ, Arrobio J, Fink R, Kim HW, Milburn C. Prospective (7 yrs) follow up (FU) and pulmonary functions (PFT) from a placebo (P) controlled randomized trial of ribavirin (R) in RSV bronchiolitis (B). Pediatr Res. May 1996. Abstract.

25. Hiatt P, Treece D, Morris L, Taber L. Longitudinal pulmonary function (PF) following treatment with ribavirin in infants hospitalized with RSV bronchiolitis. Am J Resp Crit Care Med. 1994;149:A354. Abstract.

26. Long CE, Voter KZ, Barker WH, Hall CB, Long term follow-up of children hospitalized with respiratory synicytial virus lower respiratory tract infection and randomly treated with ribavirinor placebo. Pediatr Infect Dis J. 1997;16:1025-8.

27. Whimbey E. Community respiratory viral infections in the immunocompromised host (Introduction). Am J Med. 1997;102(suppl 3a):1.

28. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997;102(suppl 3a):2-9.

29. Leshin L. Respiratory syncytial virus (RSV). www.KidsHealth.org. 1996.

30. Groothuis JR, Woodin KA, Katz R, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr. 1990;117:792-798.

31. Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA. 1985;254:3047-3051.

32. McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, Chanock RM, et al, eds. Virology. 2nd ed. New York, NY: Raven Press Ltd.; 1990:1045-1072.

33. ICN Physician's Guide. www.icnpharm.com. Costa Mesa, Cal: ICN Pharmaceuticals, Inc; 1996.

Back to top